Patent: 10,023,917
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,023,917
| Title: | High resolution melting analysis as a prescreening tool |
| Abstract: | Compositions and methods for determining an increased likelihood of a response to a targeted treatment of a cancer disease including isolating genomic DNA from a patient sample, amplifying a fragment of DNA by means of PCR with a specific pair of amplification primers, determining if the amplified fragment comprises a wildtype sequence or a mutation by means of a High Resolution Melting Analysis (HRM), and correlating the presence or absence of a mutation with an increased likelihood of success of said targeted treatment. Respective primer pairs, compositions and kits are also claimed. |
| Inventor(s): | Buettner; Reinhard (Villiprott, DE), Froehner; Stefanie (Penzberg, DE), Merkelbach-Bruse; Sabine (Aachen, DE), Ney; Jasmin (Wallerfangen, DE), Roesler; Angelika (Sindelsdorf, DE) |
| Assignee: | Roche Molecular Systems, Inc. (Pleasanton, CA) |
| Application Number: | 14/958,567 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,023,917
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | See Plans and Pricing | 2031-01-11 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | See Plans and Pricing | 2031-01-11 |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | See Plans and Pricing | 2031-01-11 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
